Pricing Log in Create free account
Saturday 17 October 2026 Export BGLC’s income statement to Excel — free account

BioNexus Gene Lab Corp.

BGLC Basic Materials Specialty Chemicals

BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024. In the quarter to June 2026, revenue fell 96.6%, EPS grew 64.7% and free cash flow grew 44.3%, each against the same quarter a year earlier.

1.20 0.02 −1.64%
Market cap
$3.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
4/9
Altman Z
6.34
Beneish M
−3.31
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 35.47%

Capital & Financial Ratios $m

Market Cap 3.59
Revenue 3.13
Net Income (2.58)
Free Cash Flow (0.85)
Net Debt (3.48)
Current Ratio 6.08 (at or above 1.5: strong)
Debt/Equity 0.01 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E —
P/S ratio 0.93
P/B ratio 0.37
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth —
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.2×, against a ten-year median of 4.1×; over the ten years it ranged from −0.2× in 2026 to 195× in 2022.
P/S against its own 10 years 25.59%
10-year low 10-year high
P/B against its own 10 years 0.14%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 6 4 4 4
Receivables 1 2 1 0
Inventory 1 1 1 1
Other — — 0 1
8 7 5 5
2023 2024 2025 Q'26
Payables 1 2 0 0
ST’ Debt — — — —
Other 0 0 0 0
2 2 1 1

Compound Annual Growth %

10y 5y 3y
Sales — (8.20%) (12.09%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 5.28% 8.93%

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 2 2 3 0 7
’24 2 2 3 3 10
’23 2 3 3 2 10
’22 3 2 3 3 11
’21 3 3 4 3 13
’20 3 1 3 4 11
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 (1) (1) (1) 1 (2)
’24 0 (1) (2) 0 (2)
’23 0 0 (1) (1) (2)
’22 0 0 0 0 1
’21 0 (1) 0 0 0
’20 (1) 0 1 1 1
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 (1) (1) (1) 1 (2)
’24 0 (1) (2) 0 (2)
’23 0 0 (1) (1) (2)
’22 0 0 0 0 0
’21 0 (1) 0 0 0
’20 0 0 1 1 2
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.23) (0.12) — — —
’25 (0.35) (0.34) (0.39) (0.52) (1.61)
’24 (0.01) 0.10 (0.75) (0.26) (0.90)
’23 (0.05) (0.18) (1.56) 1.62 (0.17)
’22 0.01 (0.01) (0.05) 0.00 (0.25)
’21 0.24 0.02 0.21 0.06 0.53
’20 1.25 (0.04) 0.27 (0.21) 1.28
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 84.00 19.20 3.10 2.11 2.01

Analyst estimates 2026–2028

Powerpack
High — — — — — 322.80 267.60 178.80 33.90 15.60
People
People Employees — — — 9 9 13 6 18 21 6
Revenue/emp, $m — — 0.00 0.01 1.27 1.03 1.82 0.54 0.45 1.24
Income, $m
Income, $m Revenue — — 0 0 11 13 11 10 10 7
Gross margin, % — — 13.57 44.02 15.10 16.96 11.52 13.61 13.56 14.62
EBT — — 0 0 1 1 0 (3) (2) (3)
EBT margin, % — — 28.21 (217.09) 11.08 7.80 (2.78) (26.69) (16.77) (40.20)
Net income — — 0 0 1 1 0 (3) (2) (3)
Depreciation — — 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue — — 0.38 0.18 13.29 9.37 7.58 0.62 5.34 4.00
Earnings — — 0.05 (0.34) 1.28 0.53 (0.25) (0.17) (0.90) (1.61)
Cash flow — — (0.50) (0.30) 0.64 0.01 0.38 (0.11) (1.17) (0.99)
Capex — — (0.07) (0.02) 1.22 0.00 (0.04) (0.01) (0.13) (0.02)
Free cash flow — — (0.57) (0.32) 1.87 0.00 0.35 (0.12) (1.30) (1.01)
Book value — — 2.75 1.56 7.77 5.03 4.63 0.61 4.67 4.64
Shares, m — — 1 1 1 1 1 16 2 2
Valuation, ×
Valuation, × P/E — — 206.86 206.86 206.86 485.01 0.00 0.00 0.00 0.00
P/S — — 19.87 19.87 19.87 27.28 15.82 8.48 0.52 0.99
P/B — — 33.97 33.97 33.97 50.77 25.94 8.58 0.60 0.85
EV/Sales — — 19.63 19.63 19.63 27.12 15.63 7.89 0.08 0.46
EV/FCF — — 139.83 139.83 139.83 60,404.27 343.33 (39.08) (0.31) (1.81)
Cash, $m
Cash, $m Operating cash flow — — 0 0 1 0 1 (2) (2) (2)
Capex — — 0 0 1 0 0 0 0 0
Free cash flow — — 0 0 2 0 0 (2) (2) (2)
Balance, $m
Balance, $m Working capital — — 1 1 5 5 4 6 5 5
Total debt — — 0 0 0 0 0 — — —
Net debt — — (1) (1) (3) (2) (2) (6) (4) (4)
Shareholders’ equity — — 2 1 7 7 7 10 8 9
Returns, %
Returns, % ROA — — 0.00 (17.10) 19.29 7.63 (3.89) (26.11) (14.64) (30.32)
ROIC — — 11.53 (55.87) 20.36 13.02 (4.00) (43.47) (24.93) (40.51)
ROE — — 0.00 (18.64) 28.11 10.86 (5.14) (32.21) (17.78) (35.24)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

BioNexus Gene Lab Corp. vs peers in Specialty Chemicals (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LOOP Loop Industries, Inc. $18.0M — (loss-making) — (loss-making) −98.34% (below 0%: shrinking) n/m +60.46% (above 0%: growing) 0.00% (1,463.69%) Compare
TSEOQ Trinseo PLC $9.5M — (loss-making) — (loss-making) +7.79% (above 0%: growing) n/m −4,036.67% (below 0%: shrinking) 11.79% 0.01% Compare
BON Bon Natural Life Limited $9.2M 0.9× 4.5× +20.95% (above 0%: growing) −14.29% (below 0%: shrinking) −260.38% (below 0%: shrinking) 33.34% 0.00% Compare
YMAT J-Star Holding Co., Ltd $6.1M — — — — — — — Compare
CRKN Crown Electrokinetics Corp. $5.8M — (loss-making) 0.3× +306.45% (above 0%: growing) n/m −362.52% (below 0%: shrinking) (36.69%) (357.14%) Compare
SNES Senestech, Inc. $3.8M — (loss-making) — (loss-making) +23.20% (above 0%: growing) n/m −42.77% (below 0%: shrinking) 73.64% (241.82%) Compare
BGLC BioNexus Gene Lab Corp. $3.6M — (loss-making) — −96.63% (below 0%: shrinking) n/m +44.32% (above 0%: growing) 17.06% (342.78%)
CNEY CN Energy Group. Inc. $3.3M 2.3× 1.1× −99.90% (below 0%: shrinking) +33.33% (above 0%: growing) −113.57% (below 0%: shrinking) 3.28% 0.00% Compare
HGAS Global Gas Corporation $1.1M — (loss-making) — — n/m −333.93% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $5.9M — 1.1× +14.37% — −260.38% 11.79% 0.00%

All 60 Specialty Chemicals stocks →

BioNexus Gene Lab Corp. (BGLC) key facts

  • Concern: BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024.
  • BioNexus Gene Lab Corp. (BGLC) is a Specialty Chemicals company in the Basic Materials sector, listed on Nasdaq.
  • As of October 16, 2026, BGLC traded at $1.20, a market capitalization of $3.6 million.
  • Return on equity was −35.2% and debt-to-equity 0.01.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 6.34 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

BioNexus Gene Lab Corp. (BGLC) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/BGLC · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com